key: cord-0925568-blfpxnxn authors: Jouan, Youenn; Baranek, Thomas; Si-Tahar, Mustapha; Paget, Christophe; Guillon, Antoine title: Lung compartmentalization of inflammatory biomarkers in COVID-19-related ARDS date: 2021-03-24 journal: Crit Care DOI: 10.1186/s13054-021-03513-9 sha: 6f133658a7ffe532b9e2d9b3151e2584d5412feb doc_id: 925568 cord_uid: blfpxnxn nan We read with great interest the article of Bendib et al. published in Critical Care [1] , in which they systematically assessed inflammatory mediators in pneumoniarelated ARDS, both in airways and blood compartments. The authors observed a lung compartmentalization of inflammatory mediators, with important heterogeneity in the bronchoalveolar lavage fluid-to-serum concentration ratios across the mediators screened. The concept of compartmentalization of inflammation has already been formulated in pneumonia [2] , and issues raised by assessing lung inflammation using blood inflammatory markers has also been highlighted, as well as the subsequent limitations of these biomarkers for bedside management [3] . However, we believe that it is critical to examine it further in ARDS, in this COVID-19 era. Indeed, since the beginning of the pandemic, most of the studies exploring immune dysregulation during COVID-19 were nevertheless based on data obtained only from blood, not because this is the most relevant compartment, but because it is the most easily accessible. In complement to the work of Bendib et al., we evaluated coincident inflammatory mediators in blood and respiratory fluids (endotracheal aspirates [ETA]) of 21 critically ill COVID-19 patients with ARDS requiring mechanical ventilation, within 48 h of their admission in ICU. As observed by Bendib et al., we found an increased ETA-to-blood concentration ratio for IL-8, the cytokine for which concentration was the most compartmentalized to the lung. However, in our COVID-19 ARDS cohort, the median (quartile 1; quartile 3) ratio was highly elevated: 7355 (1959; 22433), compared to 20 in the study of Bendib et al. Moreover, ETA to blood concentration ratios of IL-1RA, IL-6, IFN-γ, TNF-α and CXL10 were also highly elevated ( Fig. 1) , at a higher level than those reported by Bendib et al. for ARDS without shock. Thus, during COVID-19-driven ARDS -and even compared to non-COVID-pneumonia-related ARDSinflammation appears highly compartmentalized to the lungs. These results are in line with publications reporting relatively low levels of systemic inflammatory mediators compared to other conditions requiring ICU [4, 5] . Taken together, these data challenge the concept of "systemic cytokine-storm" that has been employed to describe immune dysregulation during severe COVID-19. Consequently, in our quest of identifying reliable biomarker in pneumonia-induced ARDS -whether COVID or not-, lungs should not be excluded. We thank Jouan et al. for their letter related to our recently published article [1] . Although serum This comment refers to the article available online at https:// doi. org/ 10. 1186/ s13054-020-03427-y. *Correspondence: antoine.guillon@univ-tours.fr 3 Service de Médecine Intensive Réanimation, Centre Hospitalier Régional Universitaire, 2 Bd Tonnellé, 37044 Tours Cedex 9, France Full list of author information is available at the end of the article biomarkers can depict specific profiles in patients with ARDS associated with COVID-19 and other diseases [6] , the degree of cytokine release is markedly lower in critically ill COVID-19 than in other disorders associated with elevated cytokines (e.g., non-COVID-19 ARDS, sepsis, CAR-T cell therapy) [7] . Assessing the production of lung borne cytokines might thus be particularly relevant in COVID-19 patients. Consistent with our results in non-COVID-19 ARDS patients, Jouan et al. showed in patients with severe SARS-CoV-2 infection that the highest endotracheal aspirates (ETA) to blood concentration ratio was observed for interleukin-8 (IL-8). The authors pointed out some differences regarding the magnitude of the concentration gradient they measured (median value of the ETA to blood ratio of IL-8: 7355) and ours, which included only non-COVID-19 patients with pneumoniaassociated ARDS (median value of the broncho-alveolar lavage (BAL) to serum ratio of IL-8: 21). Such magnitude difference might be due to the following factors: (1) a dilution of BAL fluid samples; (2) differences in IL-8 concentrations in proximal vs. distal airways and hypothetically, (3) higher IL-8 lung to blood concentration ratios in COVID-19 than in non-COVID-19 patients. ETA to blood concentration ratios of other cytokines, including interleukin-6 were also highly elevated in COVID-19 patients in the letter of Jouan et al. However, the clinical implications of these findings need to be investigated. Further studies will be needed to assess whether measuring lung to blood concentration ratios of selected biomarkers could help target patients most likely to benefit from immunomodulating drugs targeting cytokine pathways [8] . Ready to submit your research Ready to submit your research ? Choose BMC and benefit from: ? Choose BMC and benefit from: Alveolar compartmentalization of inflammatory and immune cell biomarkers in pneumonia-related ARDS Integrative physiology of pneumonia Biomarkers for the acute respiratory distress syndrome: how to make the diagnosis more precise COVID-19: more than a cytokine storm Cytokine levels in critically Ill patients with COVID-19 and other conditions Uncontrolled innate and impaired adaptive immune responses in patients with COVID-19 ARDS Cytokine elevation in severe and critical COVID-19: a rapid systematic review, meta-analysis, and comparison with other inflammatory syndromes Exploring pharmacological approaches for managing cytokine storm associated with pneumonia and acute respiratory distress syndrome in COVID-19 patients Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations Not applicable. Authors' contributions YG, TB, MST, CP and AG were involved in drafting the manuscript. All authors read and approved the final manuscript. No funding was used for this study. The datasets used and/or analyzed for this research letter are available from the corresponding author on reasonable request. All patients or their next of kin gave consent for participation in the study cited in this research letter. This work was part of an ongoing study exploring immune response during community-acquired pneumonia (ClinicalTrial.gov identifier: NCT03 379207). The study was approved by the ethic committee "Comité de Protection de Personnes Ile-de-France 8" under the agreement number 2017-A01841-52, in accordance with the national laws. Not applicable. No competing interests to declare.